Krystal Biotech's CEO to participate in investor conferences on December 3 and 4, 2024, with live webcasts available.
Quiver AI Summary
Krystal Biotech, Inc. announced that CEO Krish S. Krishnan will participate in fireside chats and host investor meetings at two investor conferences: Citi’s 2024 Global Healthcare Conference on December 3 in Miami and the 7th Annual Evercore HealthCONx Conference on December 4 in Coral Gables. Both presentations will be available via live webcasts, with archived versions accessible on the Company’s website for 30 days. Krystal Biotech focuses on developing genetic medicines addressing unmet medical needs, with its first product, VYJUVEK®, being the first approved gene therapy for dystrophic epidermolysis bullosa. The company is expanding its pipeline in areas such as respiratory, oncology, and dermatology.
Potential Positives
- Krystal Biotech's CEO will engage in investor conferences, enhancing visibility and investor relations.
- The company has a significant product, VYJUVEK®, which is the first-ever redosable gene therapy, showcasing its innovative capabilities in biotechnology.
- Krystal Biotech is focused on addressing high unmet medical needs, highlighting its commitment to impactful healthcare solutions.
- The company has a diverse pipeline in various medical fields, indicating strong potential for future growth and product development.
Potential Negatives
- None
FAQ
What upcoming investor conferences will Krystal Biotech attend?
Krystal Biotech will participate in Citi’s 2024 Global Healthcare Conference and the 7th Annual Evercore HealthCONx Conference.
Who will represent Krystal Biotech at the conferences?
Krish S. Krishnan, Chairman and Chief Executive Officer, will represent Krystal Biotech at the investor conferences.
When are the fireside chats scheduled?
The fireside chats are scheduled for December 3, 2024, at 8:45 am ET and December 4, 2024, at 2:10 pm ET.
How can I access the live webcasts of the presentations?
The live webcasts can be accessed via a link in the Investors section of Krystal Biotech's website.
What is VYJUVEK®?
VYJUVEK® is Krystal Biotech's first commercial product, a redosable gene therapy approved for treating dystrophic epidermolysis bullosa.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$KRYS Insider Trading Activity
$KRYS insiders have traded $KRYS stock on the open market 62 times in the past 6 months. Of those trades, 0 have been purchases and 62 have been sales.
Here’s a breakdown of recent trading of $KRYS stock by insiders over the last 6 months:
- KRISH S KRISHNAN (President and CEO) has traded it 31 times. They made 0 purchases and 31 sales, selling 100,000 shares.
- SUMA KRISHNAN (President, R&D) has traded it 31 times. They made 0 purchases and 31 sales, selling 100,000 shares.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$KRYS Hedge Fund Activity
We have seen 159 institutional investors add shares of $KRYS stock to their portfolio, and 134 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- UBS ASSET MANAGEMENT AMERICAS LLC added 233,501 shares (+1278.7%) to their portfolio in Q2 2024
- REDMILE GROUP, LLC removed 210,833 shares (-20.6%) from their portfolio in Q3 2024
- AVORO CAPITAL ADVISORS LLC added 189,222 shares (+7.8%) to their portfolio in Q3 2024
- PRICE T ROWE ASSOCIATES INC /MD/ removed 161,886 shares (-27.0%) from their portfolio in Q3 2024
- SEGALL BRYANT & HAMILL, LLC added 122,407 shares (+352.4%) to their portfolio in Q3 2024
- GOLDMAN SACHS GROUP INC removed 120,977 shares (-28.6%) from their portfolio in Q3 2024
- STATE STREET CORP added 119,936 shares (+9.0%) to their portfolio in Q3 2024
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
PITTSBURGH, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc . (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that Krish S. Krishnan, Chairman and Chief Executive Officer, will take part in fireside chats and host investor meetings at two upcoming investor conferences:
- Citi’s 2024 Global Healthcare Conference on December 3, 2024 in Miami, Florida; fireside chat scheduled for 8:45 am ET
- 7th Annual Evercore HealthCONx Conference on December 4, 2024 in Coral Gables, Florida; fireside chat scheduled for 2:10 pm ET
Each presentation will be webcast live and may be accessed through a link on the Investors section of the Company’s website . Archived versions of the webcasts will also be available on the Investors section of the Company’s website for at least 30 days.
About Krystal Biotech, Inc.
Krystal Biotech, Inc. (NASDAQ: KRYS) is a commercial-stage biotechnology company focused on the discovery, development and commercialization of genetic medicines to treat diseases with high unmet medical needs. VYJUVEK ® is the Company’s first commercial product, the first-ever redosable gene therapy, and the first medicine approved by the FDA for the treatment of dystrophic epidermolysis bullosa. The Company is rapidly advancing a robust preclinical and clinical pipeline of investigational genetic medicines in respiratory, oncology, dermatology, ophthalmology, and aesthetics. Krystal Biotech is headquartered in Pittsburgh, Pennsylvania. For more information, please visit http://www.krystalbio.com , and follow @KrystalBiotech on LinkedIn and X (formerly Twitter).
CONTACT
Investors and Media:
Stéphane Paquette
Krystal Biotech
[email protected]
